The global progressive pulmonary fibrosis (PPF) treatments market is anticipated to grow at a compound annual growth rate (CAGR) of 7.5% from 2023 to 2033, with a projected value of US$ 3.72 million in 2023. Future therapy options for idiopathic pulmonary fibrosis appear to include a number of investigational cancer medications. Additionally, major players are putting more of an emphasis on research and development, which will open up profitable growth prospects for the market for treatments for progressive pulmonary fibrosis (PPF).
PPF is a debilitating lung disease characterized by scarring of the lung tissue. There is currently no cure for PPF, but new treatment options are emerging that offer hope for patients.
As the field of image processing and analysis advances, deep learning-based machine learning applications create new avenues for applying deep learning and radio mics to picture analysis. Validating radiological biomarkers against pertinent illness outcome predictions and developing improved algorithms together are crucial.
Preview Next-Level Insights Sample :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16356
Antifibrotic medications, such as pirfenidone or nintedanib, have been shown in randomized clinical trials to decrease the advancement of progressive ILD linked to IPF or progressive non-IPF ILD. In its current form, the clinical management of this patient subgroup is entering a new era that presents the ideal chance to investigate as-yet-undiscovered areas within the sector.
Key Takeaways:
- The global PPF treatment market is expected to reach US$3.72 million in 2023 and grow at a CAGR of 7.5% from 2023 to 2033.
- Promising new therapies, including repurposed cancer drugs, are emerging for the treatment of IPF.
- Increased R&D activity by key players is expected to fuel market growth in the future.
Market Competition:
Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demand. End users will benefit from the use of new products and technologies by promoting them. Strategic partnerships can be formed by companies in order to increase their production capacity.
- Boehringer Ingelheim published Phase II information on BI 10015550, a new investigational PDE4B inhibitor. It was published in The New England Journal of Medicine (NEJM). An ATS Breaking News session on May 16 in San Francisco will also present promising 12-week results demonstrating a reduction in lung function decline in IPF patients. Globally acclaimed for its pulmonary fibrosis solutions, the company aspires to one day develop a cure for the debilitating chronic disease.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16356
Key Companies Profiled:
- Boehringer Ingelheim
- Bristol-Myers Squibb
- FibroGen
- Hoffmann-La Roche Ltd
- Pliant Therapeutics, Inc.
- United Therapeutics Corporation
- Galapagos
- Novartis AG
- Prometic Life Sciences Inc.
- Merck & Co., Inc.
Key Segments Profiled in the Progressive Pulmonary Fibrosis (PPF) Treatment Market Industry Survey?
By Treatment Type:
- MAPK Inhibitor
- Tyrosine Inhibitor
- Autotaxin Inhibitors
By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Treatment:
- Self-Care
- Medicines
- Pirfenidone
- Nintedanib
- Others
- Lung Transplant
- Palliative Care
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
In-Depth Market Overview: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16356
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube